NCT06459024 Master Framework For Relapse or Refractory Acute Myeloid Leukemia
| NCT ID | NCT06459024 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS |
| Condition | Acute Myeloid Leukemia, in Relapse |
| Study Type | OBSERVATIONAL |
| Enrollment | 4,000 participants |
| Start Date | 2024-06-28 |
| Primary Completion | 2032-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 4,000 participants in total. It began in 2024-06-28 with a primary completion date of 2032-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is an observational (non-interventional), prospective, cohort study that will collects data from patients diagnosed with relapsed or refractory acute myeloid leukemia afferent to the participanting clinical sites
Eligibility Criteria
Inclusion Criteria: * Patients with AML diagnosis according to WHO2022 or ICC2022 * Treatment failure (i.e. relapse, refractory or progression, including MRD) according to ELN2022 criteria * Participant or his/her legal representative is willing and able to give informed consent for participation in the study Exclusion Criteria: * Patients included in clinical trials may be enrolled except where otherwise specified in the experimental protocol.
Contact & Investigator
Giovanni Martinelli, MD, Prof
STUDY CHAIR
University of Bologna
Frequently Asked Questions
Who can join the NCT06459024 clinical trial?
This trial is open to participants of all sexes, aged 6 Years or older, studying Acute Myeloid Leukemia, in Relapse. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06459024 currently recruiting?
Yes, NCT06459024 is actively recruiting participants. Contact the research team at cc.ubsc@irst.emr.it for enrollment information.
Where is the NCT06459024 trial being conducted?
This trial is being conducted at Aachen, Germany, Greifswald, Germany, Halle, Germany, Rostock, Germany and 11 additional locations.
Who is sponsoring the NCT06459024 clinical trial?
NCT06459024 is sponsored by Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS. The principal investigator is Giovanni Martinelli, MD, Prof at University of Bologna. The trial plans to enroll 4,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.